Yasserged
@yasserged
Followers
105
Following
47
Media
0
Statuses
44
GU Medical Oncologist @hopkinskimmel Irish Trained Medical Oncologist Former GU Oncology Fellow @MSKCC Views are my own....
Baltimore, Maryland
Joined January 2019
Looking forward to a great line-up with GU onc experts from @brady_urology @hopkinskimmel @HopkinsMedicine @sibleyonline featuring @yasserged @CathyHandy @JCensits @akfsurgeon & Mohit Narang. Dinner and great networking opportunity. Thank you @MJHLifeSciences @OncLive !
The future of GU oncology starts with insights from @nirmishsingla, @CathyHandy, @JCensits, Mohit Narang, MD, & Yasser Mohamed Ali Ged, MBBS at the Genitourinary Cancers #OncLiveSOSS on June 10th! Don't miss out! Register Now: https://t.co/dJ9Ns31CzH
@hopkinskimmel
0
7
19
💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 @nirmishsingla @AdityaBagrodia Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases
1
76
167
We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy https://t.co/0Qpox9xWG2
cell.com
An upregulation of the HIF2 transcription factor, which is a hallmark of the most common form of human kidney cancer, drives the expression of multiple relatively intact endogenous retroviruses,...
7
52
156
Our new study in JITC introduces a dual ERV-based stratification system for predicting immunotherapy efficacy in metastatic ccRCC patients. The model outperforms traditional transcriptomic signatures, offering enhanced precision for ICI treatment outcomes. @jitcancer 🙏Xiaofan Lu
New #JITC article: Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma https://t.co/l4JCEdr1ib
@GabrielMalouf
0
5
15
It’s an honor to present my poster at #ASCOGU. Sharing our findings on the impact of Area Deprivation Index on Immunotherapy outcomes in mRCC. Stop by poster D13 to discuss! #CancerResearch #ASCOGU25
0
3
9
Congratulations, Dr. Noah Hahn of @hopkinskimmel and all co-authors on presentation of ADAPT-BLADDER (HCRN-GU16-243) Cohort 4 results at #GU25.
0
8
19
Ab#437 @ASCO #GU25 by @VincentWenxinXu👉 https://t.co/uiBniVraFJ👉post-hoc analysis of CheckMate214 #kidneycancer👉⬆️KIM-1 associated w/⬇️OS & KIM-1 reduction correlates w/⬆️ Ipi+Nivo efficacy👇 @OncoAlert @urotoday @Uromigos @KidneyCancer @kidneycan
0
20
38
🚨 New AI Tool for Immunotherapy Prediction! 🧠💊 A deep learning model predicts response to ICI in advanced NSCLC using H&E pathology slides! 🏥🔬 ✅ Outperforms biomarkers like PD-L1 & TMB ✅ May improve selection for immunotherapy ✅ Hope to see in other tumor types!
⚠️Great to keep contributing to this ongoing effort by #MehrdadRakaee and collaborators! @DanaFarber Histology slides are widely available and can harbor useful information in low-resource settings. This is 1 application in the NSCLC/ICI space. #lcsm
https://t.co/B81JcWchSU
0
1
5
Coming from a patient point of view this is big stuff coming from @DanaFarber @YaleCancer @BraunMDPhD and many others!
1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin
1
5
10
Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. https://t.co/Gyk6VOxsA0
@nirmishsingla @montypal @KotechaMD @MattZibelman
journals.lww.com
KI combinations remains unclear. We conducted a retrospective analysis of IO combinations in mtRCC patients at 4 institutions. Eligible patients had confirmed mtRCC by genitourinary pathologist and...
2
13
41
Special thanks to Drs. Steven Schenkel & Kristin Walter @JAMA_current and @DrNDisis @JAMAOnc for the unique opportunity, & to coauthors @AdityaBagrodia @CDFankhauser @yasserged Ezra Baraban! @HopkinsMedicine @brady_urology @AmerUrological @UroOnc @Uroweb @TestesCancer @TCSociety
Testicular cancer is the most common solid malignancy in young men in the US. This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents. https://t.co/qDuhaz89Xk
1
5
25
Lots to learn from this and other ongoing trials in papillary kidney cancer. S1500 and others show us that it’s possible — please consider this trial for all your patients with this disease.
Don’t forget: @SWOG S2200 is still enrolling patients! Exciting study for a group of us in #kidneycancer who don’t have a lot of #clinicaltrial options: metastatic #papillaryRCC. The amazing @maughanonc is leading #PAPMET2. #nonclearcellRCC #renalcancer
1
7
17
Special shout out to co-surgeons @YWLum @wrburnsmd @hopkinssurgery and med onc @yasserged @hopkinskimmel So fortunate to be part of the A-team for our patients @HopkinsMedicine! Great production by @brady_urology @HopkinsMedNews highlighting Chris’s story @TestesCancer @TCSociety
"This is where we were realizing this was a much bigger situation than we thought it was" Christopher shares his remarkable #testicularcancer journey and how it led him to @HopkinsMedicine where he was treated by a multi-d team led by @nirmishsingla
https://t.co/YFo0jYZC5T
0
3
21
Can’t miss! The @OncJournal #KCRS24 abstract supplement is out! 🔗 https://t.co/NciWDV02X6
#KidneyCancer #RCC #AcceleratingCures
@OncoAlert @DrChoueiri @HHammersMD @montypal @DrRanaMcKay @arihakimi @DrYukselUrun
0
13
21
#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! @PRNews @TargetedOnc @OncLive @kidneycan @KidneyCancer @Uromigos @OncBrothers —implications beyond renal cancer ?
3
54
120
Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider @MarkowskiGUOnc
@drchristosMD
https://t.co/SFmyTxCWXb via @https://twitter.com/AmericanJIR
americanjir.com
Transarterial chemoembolization for renal cell carcinoma patients with liver metastases in the era of immunotherapy: A case series
0
2
7
Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider @MarkowskiGUOnc
@drchristosMD
https://t.co/SFmyTxCWXb via @https://twitter.com/AmericanJIR
americanjir.com
Transarterial chemoembolization for renal cell carcinoma patients with liver metastases in the era of immunotherapy: A case series
0
2
7
Just Out on @TheLancetOncol New findings from the PROSPER EA8143 trial Perioperative nivolumab before nephrectomy, followed by adjuvant nivolumab ➡️Primary endpoint was investigator-reviewed recurrence-free survival ➡️Did NOT🚫improve recurrence-free survival vs surgery only
0
9
29
Awesome talk by co-fellow Sahil Doshi @MSK_DeptOfMed reporting data from a multi-institution cohort to evaluate first line systemic therapy options in the 1st line treatment of metastatic chromophobe RCC. Really important data in a rare disease where clinical trial data are
0
18
30